Suppr超能文献

抗氨酰-tRNA合成酶抗体与间质性肺疾病的长期临床预后

Long-term clinical prognosis of anti-aminoacyl-tRNA synthetase antibodies and interstitial lung disease.

作者信息

Yamaguchi Koichi, Sullivan Daniel I, Khushboo Singh, Saygin Didem, Laverde Silvia Martinez, Moghadam-Kia Siamak, Ascherman Dana P, Oddis Chester V, Aggarwal Rohit

机构信息

Department of Allergy and Respiratory Medicine, Gunma University Graduate School of Medicine, Gunma, Japan.

Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

出版信息

Clin Rheumatol. 2025 Jun 27. doi: 10.1007/s10067-025-07521-w.

Abstract

INTRODUCTION

Anti-aminoacyl tRNA synthetase (anti-ARS) antibody is the most common myositis-specific antibody subtype. Anti-ARS antibody-positive myositis is often complicated by interstitial lung disease (ILD), but the clinical progression of anti-ARS antibody-positive ILD (ARS-ILD) remains unclear.

METHOD

A prospectively collected, single center longitudinal myositis database was used to retrospectively investigate 131 patients with ARS-ILD based on subtypes of anti-ARS antibodies (Jo-1, PL-7, PL-12, EJ, OJ, and KS). We investigated the occurrence and associated risk factors for pulmonary events, including lung transplantation and pulmonary death, as well as overall mortality at both 5 and 10 years.

RESULTS

This cohort included those with myositis (n = 97), anti-synthetase syndrome without myositis (n = 17), and other connective tissue diseases (n = 17). In a 5-year period, the overall mortality rate and incidence of pulmonary events were both 15%. Across a 10-year timespan, the overall mortality rate increased to 28%, with pulmonary events observed in 24% of cases. A multivariate analysis during the 5-year follow-up, identified poor prognostic factors for overall mortality included dysphagia, dry eyes, usual interstitial pneumonia (UIP) pattern, and the presence of anti-PL-7 antibody. In the 10-year follow-up, dysphagia, diffusing capacity for carbon monoxide (DLCO)%, and anti-PL-7 antibody were associated with increased mortality. Risk factors for pulmonary events at 5 years were DLCO% and UIP pattern, while at 10 years, dysphagia and DLCO% were significant poor prognosis factors.

CONCLUSIONS

Anti-PL-7 antibodies, dysphagia, UIP pattern, and decreased DLCO% predicted poor outcomes in ARS-ILD, indicating the importance of comprehensive risk assessment. Key Points • In patients with ARS-ILD, anti-PL-7 antibodies are associated with risk of all-cause mortality, and evaluation of antibody subtypes in prognosis is important. • The UIP pattern affected prognosis and pulmonary events within the first 5 years. • Dysphagia is the strongest predictor of all-cause mortality and pulmonary events, and management strategies in patients with ARS-ILD are important.

摘要

引言

抗氨酰tRNA合成酶(anti-ARS)抗体是最常见的肌炎特异性抗体亚型。抗ARS抗体阳性的肌炎常并发间质性肺疾病(ILD),但抗ARS抗体阳性的ILD(ARS-ILD)的临床进展仍不清楚。

方法

使用前瞻性收集的单中心纵向肌炎数据库,基于抗ARS抗体的亚型(Jo-1、PL-7、PL-12、EJ、OJ和KS)对131例ARS-ILD患者进行回顾性研究。我们调查了肺部事件的发生情况及相关危险因素,包括肺移植和肺部死亡,以及5年和10年时的总死亡率。

结果

该队列包括肌炎患者(n = 97)、无肌炎的抗合成酶综合征患者(n = 17)和其他结缔组织病患者(n = 17)。在5年期间,总死亡率和肺部事件发生率均为15%。在10年的时间跨度内,总死亡率升至28%,24%的病例出现肺部事件。5年随访期间的多因素分析确定,总死亡率的不良预后因素包括吞咽困难、干眼、普通型间质性肺炎(UIP)模式以及抗PL-7抗体的存在。在10年随访中,吞咽困难、一氧化碳弥散量(DLCO)%和抗PL-7抗体与死亡率增加相关。5年时肺部事件的危险因素是DLCO%和UIP模式,而在10年时,吞咽困难和DLCO%是显著的不良预后因素。

结论

抗PL-7抗体、吞咽困难、UIP模式和DLCO%降低预示着ARS-ILD的不良预后,表明综合风险评估的重要性。要点 • 在ARS-ILD患者中,抗PL-7抗体与全因死亡率风险相关,评估抗体亚型对预后很重要。 • UIP模式在前5年内影响预后和肺部事件。 • 吞咽困难是全因死亡率和肺部事件的最强预测因素,ARS-ILD患者的管理策略很重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验